# Bioequivalence and Safety of Vantobra and TOBI in Healthy Subjects

> **NCT01953367** · PHASE1 · COMPLETED · sponsor: **Pari Pharma GmbH** · enrollment: 72 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Vantobra (tobramycin)
- **DRUG:** TOBI (tobramycin)

## Key facts

- **NCT ID:** NCT01953367
- **Lead sponsor:** Pari Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2014-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01953367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01953367, "Bioequivalence and Safety of Vantobra and TOBI in Healthy Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01953367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*